NetworkNewsBreaks – VolitionRx Ltd. (NYSE American: VNRX) Reports Multi-Pillar Clinical and Commercial Progress
VolitionRx Ltd. (NYSE American: VNRX) (“Volition”), a multi-national epigenetics company, provided a consolidated update highlighting recent clinical and commercial progress across its key platforms. The company highlighted submission of a manuscript for peer review, showcasing both a new method, Capture-Seq, and new biomarkers for the detection of cancer, which it estimates represents an annualized total addressable market opportunity of approximately $23 billion. Commercialization of the Nu.Q Cancer assay progressed in lung cancer, with the company reporting reimbursement submission in France on track, and routine clinical use expected by Q4 2026. Volition also confirmed inclusion of its Nu.Q NETs assay in the $7.3 million government-backed DETECSEPS program in France for early detection of sepsis and further highlighted new clinical utility data for its assay in Hidradenitis Suppurativa, noting CE-marked availability across Europe. The company…







